Avantor Inc.

Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The firm operates through the following segments: the Americas, Europe, and AMEA. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avantor meets Q4 expectations, eyes bioproduction growth in 2023

Avantor delivered solid financial performance in Q4 and exceeded full-year revenue targets.
The company's focus on operational enhancements and global expansion supports future growth.
Challenges in the first quarter are being addressed with a focus on productivity and cost management.
Opportunities in bioproduction growth, M&A, and working capital improvements position Avantor for success.

Avantor Inc. reports Q1 revenue decline, eyes semiconductor market rebound

Avantor Inc. navigated challenges in Q1 with revenue declines due to destocking and semiconductor downturn, while showcasing strengths in innovation and acquisitions performance.
Management's confidence in the long-term strategy and focus on margin improvement present opportunities for growth and recovery in 2023, despite ongoing market challenges.
Strategic approaches to address destocking headwinds and market dynamics in different regions position Avantor Inc. for potential growth and resilience in the coming quarters.
Overall, Avantor Inc. faces challenges from market uncertainties but remains poised to leverage opportunities for growth, innovation, and margin improvement in the evolving landscape.

Avantor Inc. reports Q2 revenue decline, focuses on cost controls

Avantor Inc. faced revenue and EPS cuts in Q2 2023, driven by market challenges in biopharma and semiconductors. The company focused on cost savings, debt reduction, and operational efficiency. Challenges included limited visibility in research space and mid- to high single-digit organic decline in bioproduction.

Avantor Inc. reports Q3 revenue contraction, eyes growth opportunities

Avantor Inc. navigated challenges in Q3 2023 with a focus on growth and operational improvements.
Management's cautious yet optimistic stance reflects a strategic approach to customer sentiment and inventory health.
Outlook for 2024 remains uncertain, but the company is positioned to capitalize on opportunities in key markets.
Analyst questions addressed various topics, highlighting the company's proactive engagement with stakeholders.

Avantor Inc. exceeds Q4 expectations, eyes cost savings and margin growth

Avantor Inc. delivered solid Q4 results, focusing on executing business model transformation and driving growth strategy. Despite challenges in market conditions and revenue decline, the company is optimistic about cost-saving initiatives and margin improvement opportunities.

Avantor Inc. reports Q1 revenue decline but optimistic on growth

Avantor Inc. delivered mixed performance in Q1 2024 with revenue decline but strong margin and debt reduction. Despite challenges in certain segments and regions, the company remains optimistic about growth opportunities in key markets and cost-saving initiatives.

Avantor reports solid Q2 earnings, eyes growth in Bioprocessing segment

Avantor Inc.'s Q2 2024 performance showcased solid revenue, margin improvement, and strong segmental growth. While facing challenges in organic revenue decline and segmental performance, the company's focus on cost transformation and positive outlook signal resilience and potential for growth. Avantor's opportunities lie in leveraging Bioprocessing momentum and cost-saving initiatives for sustained performance enhancement.

Avantor Inc. reports solid Q3 performance and accelerates growth strategies

Avantor's Q3 performance reflects resilience and strategic focus amidst market challenges, with notable achievements in revenue, margin, and divestiture.
The company's strengths in innovation, operational excellence, and market positioning position it well for long-term growth and profitability.
While facing challenges in certain segments and cost transformation, Avantor's opportunities in renewable energy, cash flow, and market growth are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes biopharma, healthcare, education and government, as well as advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The company operates through the following geographical segments: the Americas, Europe, and AMEA. Avantor was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0% Net income of $93 million; Adjusted EBITDA of $306 million Diluted GAAP EPS of $0.14; adjusted EPS of $0.25 Operating cash flow of $281 million; free cash flow of $235 million RADNOR, Pa. , July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024.

Avantor® Reports Second Quarter 2024 Results

Apollo Global Management

Hibbett Sports

QuidelOrtho Corp

U.S. Silica Holdings

Schneider National

S&P Global

NEW YORK , July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.

Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

Avantor (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now

Avantor, Inc. AVTR recently released two innovative products aimed at revolutionizing the gene therapy harvest process. J.T.Baker Cell Lysis Solution and J.T.Baker Endonuclease are designed to enhance efficiency, reduce environmental impact, improve operational outcomes and preserve the integrity of viral particles.

Avantor (AVTR) Launches Solutions for Gene Therapy Harvest

Innovative Solutions Optimize the Harvest Process in Gene Therapy Manufacturing Sustainably and at Scale RADNOR, Pa. , July 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced the launch of two innovative products that together sustainably optimize the gene therapy harvest process: J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease.

Avantor® Announces New J.T.Baker® Cell Lysis Solution and J.T.Baker® Endonuclease

RADNOR, Pa. , June 28, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2024 financial results before the market opens on Friday, July 26, and will hold a conference call on the same day at 8:00 a.m.

Avantor® to Host Second Quarter 2024 Earnings Call on Friday, July 26, 2024

RADNOR, Pa. , June 21, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Corey Walker has rejoined the company as President of Avantor's Laboratory Solutions business, reporting to CEO Michael Stubblefield.

Avantor® Appoints Corey Walker as President of Laboratory Solutions

Achieves 2025 Greenhouse Gas Emission reduction goals two years ahead of schedule RADNOR, Pa., June 18, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, released its 2024 Sustainability Report today.

Avantor® Releases 2024 Science for Goodness Sustainability Report

Reasons Why You Should Retain Avantor (AVTR) Stock for Now

RADNOR, Pa. , May 29, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Fla.

Avantor® to Participate in Goldman Sachs Global Healthcare Conference

RADNOR, Pa. , May 21, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at Bernstein's 40th Annual Strategic Decisions Conference in New York on Thursday, May 30, 2024 at approximately 8:00 a.m.

Avantor® to Participate in Bernstein's 40th Annual Strategic Decisions Conference

RADNOR, Pa. , May 3, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at approximately 10:00 a.m.

Avantor® to Participate in BofA Securities 2024 Health Care Conference

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

Avantor Inc. (NYSE:AVTR ) Q1 2024 Earnings Conference Call April 26, 2024 8:00 AM ET Company Participants Christina Jones – Vice President-Investor Relations Michael Stubblefield – President and Chief Executive Officer Brent Jones – Executive Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin – Bank of America Dan Leonard – UBS Dan Brennan – TD Cowen Luke Sergott – Barclays Vijay Kumar – Evercore ISI Jack Meehan – Nephron Research Doug Schenkel – Wolfe Research Rachel Vatnsdal – JPMorgan Tejas Savant – Morgan Stanley Josh Waldman – Cleveland Research Patrick Donnelly – Citi Operator Good morning. My name is Emily, and I'll be your conference operator today.

Avantor Inc. (AVTR) Q1 2024 Earnings Call Transcript

Net sales of $1.68 billion, decrease of 5.6%; organic decline of 6.3% Net income of $60 million; Adjusted EBITDA of $283 million Diluted GAAP EPS of $0.09; adjusted EPS of $0.22 Operating cash flow of $142 million; free cash flow of $107 million RADNOR, Pa. , April 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2024.

Avantor® Reports First Quarter 2024 Results

Avantor (AVTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Avantor (AVTR) This Earnings Season?

Elevance Health Inc

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?

ELV or AVTR: Which Is the Better Value Stock Right Now?

Cigna

HCA Healthcare

Tenet Healthcare

Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.

Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat

Bausch + Lomb Corp

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?

BLCO vs. AVTR: Which Stock Is the Better Value Option?

RADNOR, Pa., April 1, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2024 financial results before the market opens on Friday, April 26, and will hold a conference call on the same day at 8:00 a.m.

Avantor® to Host First Quarter 2024 Earnings Call on Friday, April 26, 2024

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?

BLCO or AVTR: Which Is the Better Value Stock Right Now?

RADNOR, Pa. and LISBON, Portugal , Feb. 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, recognized supplier excellence across a range of categories and products at its 2024 European Sales Conference in Lisbon, Portugal earlier this month.

Avantor® Celebrates Supplier Award Honorees at 2024 European Sales Conference

Hanmi Financial

Cactus

HAFC, AVTR and WHD have been added to the Zacks Rank #5 (Strong Sell) List on February 20, 2024.

News for Avantor Inc. Stock (AVTR)